A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

NCT03207867 PHASE2 TERMINATED Results posted

The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE2
Status	TERMINATED
Enrolment	315
Start date	Mon Aug 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• NSCLC, Non Small Cell Lung Cancer
• RCC, Renal Cell Cancer
• Pancreatic Cancer
• Urothelial Cancer
• Head and Neck Cancer
• DLBCL, Diffused Large B Cell Lymphoma
• MSS, Microsatellite Stable Colon Cancer
• TNBC, Triple Negative Breast Cancer
• Melanoma
• mCRPC, Metastatic Castration Resistant Prostate Cancer

Interventions

• NIR178
• PDR001

Countries

France, Italy, Japan, Netherlands, Belgium, Austria, Taiwan, Germany, Argentina, Switzerland, Australia, Singapore, United States, Spain, Czechia